文献速递心脑血管急症重症综合管理与镇静镇痛

量化脑萎缩与大缺血性卒中严重占位效应的风险

Quantified Brain Atrophy and Risk of Severe Mass Effect in Acute Ischemic Stroke.
PubMed 文献 · Neurocrit Care · 2026-10-30
一句话结论在大脑中动脉大面积梗死患者中,入院CT量化的脑萎缩程度越高,后续出现中线移位≥5 mm的风险越低,且可提升现有模型的预测效能。

该回顾性队列研究纳入2006—2024年两家综合卒中中心收治的565例梗死范围≥1/2大脑中动脉供血区、发病24小时内且至少有一次随访头颅CT的患者,以入院CT标准化脑体积的倒数量化脑萎缩。主要终点为随访CT显示中线移位≥5 mm的严重影像学占位效应,发生率为39.5%。脑萎缩程度越高,严重占位效应的比值比越低(OR 0.44,95%CI 0.34-0.58),但与院内死亡率无关;将脑萎缩纳入模型后预测严重占位效应的AUC由0.60升至0.68。提示该影像生物标志物或有助于早期风险分层、监测与干预计划。

要点

  • 适用人群为梗死范围≥1/2大脑中动脉供血区、发病24小时内、至少有一次随访头颅CT的大面积缺血性卒中患者。
  • 脑萎缩以入院头颅CT标准化脑体积的倒数量化,数值越大表示萎缩越重。
  • 脑萎缩程度越高,随访CT中线移位≥5 mm的比值比越低(OR 0.44,95%CI 0.34-0.58)。
  • 脑萎缩与院内死亡率无显著关联(原文未给出具体效应值)。
  • 将脑萎缩加入基线模型后,预测严重占位效应的AUC由0.60升至0.68(似然比检验χ2(1)=41,p<0.001)。

适用人群与场景

  • 梗死范围≥1/2大脑中动脉供血区、发病至就诊时间在最后已知正常时间24小时内、至少有一次随访头颅CT的急性缺血性卒中患者。
  • 研究在两家拥有综合卒中中心的学术医院进行,2006—2024年收治的565例患者,平均年龄67.5±15.7岁,女性49.9%。

诊断标准与关键阈值

  • 主要终点严重影像学占位效应定义为随访头颅CT上中线移位≥5 mm。
  • 脑萎缩量化为入院头颅CT标准化脑体积的倒数。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 随访CT出现中线移位≥5 mm的严重影像学占位效应是需要重点识别的危及生命的脑水肿表现,原文未给出具体处理措施。

研究设计与关键结果

  • 回顾性观察性队列研究,纳入565例大面积大脑中动脉梗死患者(两家综合卒中中心,2006—2024年),平均年龄67.5±15.7岁,女性49.9%。
  • 223例(39.5%)发生严重占位效应(中线移位≥5 mm)。
  • 脑萎缩程度越高,中线移位≥5 mm的比值比越低(OR 0.44,95%CI 0.34-0.58),但与院内死亡率无显著关联。
  • 将脑萎缩纳入模型后预测严重占位效应的效能提升(似然比检验χ2(1)=41,p<0.001;AIC 703 vs. 741;BIC 733 vs. 767;AUC 0.68 vs. 0.60)。

证据类型、等级与局限

  • 证据类型为回顾性观察性队列研究。
  • 局限:回顾性设计、仅两家中心、样本量565例,脑萎缩与院内死亡率的关系未给出具体效应值。

对床旁实践的改变

  • 对大面积大脑中动脉梗死患者,入院头颅CT量化的脑萎缩可作为早期风险分层工具,帮助识别严重占位效应风险较低者,从而调整监测与干预计划。
  • 脑萎缩预测模型AUC仅0.68,不能单独作为决策依据;原文未说明其对死亡率预测的价值。
  • 原文未提及该指标对治疗决策(如去骨瓣减压)的影响,不能据此改变干预指征。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Large middle cerebral artery (MCA) infarctions can result in life-threatening cerebral edema. Quantitative brain atrophy may improve risk stratification for severe edema. We examined whether quantitative brain atrophy is associated with severe midline shift after large ischemic stroke and whether incorporating atrophy improves prediction beyond established clinical and radiographic predictors.

METHODS: This was a retrospective observational cohort study of patients with greater than or equal to half MCA ischemic infarction, presentation within 24 h of last known well time, and at least one follow-up head computed tomography (CT), admitted to two academic hospitals with comprehensive stroke centers between 2006 and 2024. The study was approved by the institutional review boards of both centers. Brain atrophy was quantified as the inverse of standardized brain volume on admission head CT. The primary outcome was severe radiographic mass effect, defined as midline shift ≥ 5 mm on follow-up CT. The secondary outcome was in-hospital mortality. Multivariable regression models assessed associations between quantified atrophy and outcomes. Incremental prognostic value was evaluated by comparing models with and without atrophy using measures of goodness of fit, calibration, and discrimination.

RESULTS: Among 565 patients (mean age 67.5 ± 15.7 years; 49.9% female), 223 (39.5%) developed severe mass effect. Greater atrophy was associated with lower odds of midline shift ≥ 5 mm [odds ratio (OR) 0.44, 95% confidence interval (CI) 0.34-0.58], but not with in-hospital mortality. Incorporation of atrophy improved prediction of severe mass effect compared with the baseline model [likelihood ratio test χ2 (1) = 41, p < 0.001; Akaike information criterion (AIC) 703 vs. 741; Bayesian information criterion (BIC) 733 vs. 767; area under the receiver operating characteristic curve (AUC) 0.68 vs. 0.60].

CONCLUSIONS: Quantified brain atrophy is independently associated with a reduced risk of severe mass effect after large MCA stroke and improved the performance of established predictive models. Incorporation of this imaging biomarker may enhance early risk stratification, monitoring, and intervention planning for patients at risk of life-threatening cerebral edema.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Du Y, Altaf AZ, Ibrahim NJ, et al. Quantified Brain Atrophy and Risk of Severe Mass Effect in Acute Ischemic Stroke. Neurocrit Care. 2026. PMID: 42963517. doi:10.1007/s12028-026-02660-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。